Over 20% of epileptic patients are resistant to treatment with the currently available antiepileptic drugs (AEDs). Only for a subset of such drug-resistant (DR) patients brain surgery is suitable. Several new compounds have been recently introduced in therapy, decreasing significantly the number of DR patients. Other putative AEDs are in advanced stage of clinical evaluation. The present review briefly deals with data available in the literature on felbamate, gabapentin, lamotrigine and vigabatrin. Furthermore, the authors report their own data regarding the use of vigabatrin either as 'add-on therapy' in patients with DR partial epilepsy, either as monotherapy in newly diagnosed patients with symptomatic or cryptogenic partial epilepsy.
|Translated title of the contribution||New antiepileptic drugs|
|Number of pages||22|
|Journal||Neurologia Psichiatria Scienze Umane|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Neuropsychology and Physiological Psychology